Expressing the sense of the House of Representatives that the Food and Drug Administration has the authority to approve drugs for abortion care.

This resolution expresses the sense of the House of Representatives that the Food and Drug Administration (FDA) has the authority to review and approve drugs pursuant to its own expertise, and that recent court decisions blocking the FDA's approval of mifepristone (which is used in medication abortion) violate congressional intent with respect to the FDA's authority.

Bill 118 HRES 309, titled "Expressing the sense of the House of Representatives that the Food and Drug Administration has the authority to approve drugs for abortion care," is a resolution that was introduced in the US Congress. The purpose of this resolution is to affirm the belief that the Food and Drug Administration (FDA) has the authority to approve drugs that are used for abortion care.

The resolution emphasizes the importance of ensuring that the FDA is able to fulfill its regulatory responsibilities in a timely and efficient manner, particularly when it comes to approving drugs that are used for abortion care. It also highlights the need for the FDA to base its decisions on scientific evidence and medical expertise, rather than political considerations.

The resolution does not seek to change any existing laws or regulations related to abortion care. Instead, it simply expresses the opinion of the House of Representatives that the FDA should be able to carry out its duties without interference or obstruction. Overall, Bill 118 HRES 309 is a non-binding resolution that serves to reaffirm the belief that the FDA has the authority to approve drugs for abortion care. It is a statement of support for the FDA's regulatory role in ensuring the safety and efficacy of medications used in abortion procedures.